FINWIRES · TerminalLIVE
FINWIRES

BP Expands Venezuela Gas Push With Cocuina-Manakin Deal

By

-- BP (BP) on Wednesday signed a memorandum of understanding with Venezuela to develop the Cocuina-Manakin gas field near Trinidad and Tobago.

The agreement was signed in Caracas with the Venezuelan government, establishing potential areas for co-operation in material offshore gas and future exploration, the company said in response to aninquiry.

The MOU was signed during a senior BP delegation visit to Venezuela this week, led by BP Executive Vice President William Lin, the company said.

Under the agreement, the energy firm will take the lead in developing the Cocuina-Manakin field near the Trinidad and Tobago border while assessing additional exploration prospects in the Loran offshore block, according to media reports.

The partnership also reportedly covers joint work on exploration and gas commercialization in the Loran area, where interest from other global players, including Shell (SHEL), continues to build.

Venezuela has accelerated efforts to attract foreign operators, signing new agreements with companies such as Eni (E) and Repsol to expand upstream production capacity, multiple media outlets reported.

The MOU sets out cooperation across gas development and future exploration projects, with state-owned Petroleos de Venezuela included in the arrangement.

Lin reportedly said the company is strengthening its footprint in the country by establishing a permanent office in Caracas.

The agreement follows a major energy conference in Caracas that drew global investors, as companies advance long-term plans, including gas export projects expected to begin around 2031.

BP plans to channel over 1 trillion cubic feet of gas from the field into Trinidad for processing into liquefied natural gas exports, strengthening regional supply chains, the reports added.

Price: $47.23, Change: $+0.43, Percent Change: +0.92%

Related Articles

Research

Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.

$BIO
Asia

ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue

ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.

$ASX:RMD
Research

Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.

$GDDY